We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SYRS

Price
0.03
Stock movement up
+0.00 (2.88%)
Company name
Syros Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
670.81K
Ent value
38.51M
Price/Sales
1.74
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-21.16%
1 year return
-99.55%
3 year return
-86.85%
5 year return
-79.50%
10 year return
-
Last updated: 2025-04-12

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

SYRS does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales1.74
Price to Book-
EV to Sales99.78

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count26.83M
EPS (TTM)-2.49
FCF per share (TTM)-2.55

Income statement

Loading...
Income statement data
Revenue (TTM)386.00K
Gross profit (TTM)-883.00K
Operating income (TTM)-111.52M
Net income (TTM)-97.81M
EPS (TTM)-2.49
EPS (1y forward)-2.42

Margins

Loading...
Margins data
Gross margin (TTM)-228.76%
Operating margin (TTM)-28892.23%
Profit margin (TTM)-25340.67%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash58.27M
Net receivables0.00
Total current assets63.93M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment17.58M
Total assets85.00M
Accounts payable9.65M
Short/Current long term debt60.23M
Total current liabilities28.39M
Total liabilities96.12M
Shareholder's equity-11.12M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-100.02M
Capital expenditures (TTM)38.00K
Free cash flow (TTM)-100.06M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-
Return on Assets-115.08%
Return on Invested Capital-278.47%
Cash Return on Invested Capital-284.85%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.03
Daily high0.03
Daily low0.02
Daily Volume336K
All-time high237.50
1y analyst estimate1.00
Beta1.59
EPS (TTM)-2.49
Dividend per share-
Ex-div date-
Next earnings date12 May 2025

Downside potential

Loading...
Downside potential data
SYRSS&P500
Current price drop from All-time high-99.99%-14.41%
Highest price drop-99.99%-56.47%
Date of highest drop4 Apr 20259 Mar 2009
Avg drop from high-71.08%-11.07%
Avg time to new high442 days12 days
Max time to new high1931 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
SYRS (Syros Pharmaceuticals Inc) company logo
Marketcap
670.81K
Marketcap category
Small-cap
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Employees
68
Investor relations
SEC filings
CEO
Nancy A. Simonian
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...